免疫吸附辅助治疗寻常型与落叶型天疱疮的疗效与安全性
多中心随机对照试验纳入72例新诊断、复发或慢性活动性天疱疮患者,比较最佳药物治疗(BMT)与BMT联合免疫吸附(IA)。因安全性问题研究提前终止,两组达到完全缓解时间无显著差异,但BMT+IA组泼尼松累积剂量显著更低,严重不良事件在BMT+IA组更常见。
要点
- 辅助IA未缩短天疱疮达到完全缓解的时间。
- BMT+IA组泼尼松累积剂量显著低于单用BMT组。
- BMT+IA组严重不良事件更频繁,需权衡获益与风险。
核心结论
- 辅助免疫吸附未显著缩短天疱疮患者达到临床完全缓解的时间,但观察到泼尼松节省效应。
- 在广泛病变患者中,事后分析提示辅助免疫吸附可能带来更早缓解,但需谨慎权衡潜在不良事件。
研究设计与样本
- 多中心(德国和奥地利26个中心)随机对照试验,共纳入72例新诊断、复发或慢性活动性寻常型或落叶型天疱疮患者(34例女性、38例男性,年龄42-72岁)。
- 采用中央1:1随机化,比较最佳药物治疗(泼尼松1.0 mg kg-1每日联合硫唑嘌呤或霉酚酸酯)与最佳药物治疗联合免疫吸附。
- 主要终点采用Kaplan-Meier和Cox回归方法分析,研究因安全性问题在随机分配72例后提前终止。
主要发现
- 主要终点即治疗期间达到完全缓解的时间在两组间无显著差异(HR 1.35,95%CI 0.68-2.69;P=0.39)。
- BMT+IA组泼尼松累积剂量显著低于单用BMT组(差值-1214,95%CI -2225至-70;P=0.03)。
- 事后分析中,基线天疱疮疾病面积指数≥15的患者在BMT+IA组有更短缓解时间的倾向(HR 1.87,P=0.17)。
- BMT组不良事件更多(29 vs. 25),但BMT+IA组严重不良事件更频繁(10例患者17次事件 vs. 8例患者11次事件)。
关键数值与推荐
- 最佳药物治疗方案为泼尼松1.0 mg kg-1每日联合硫唑嘌呤或霉酚酸酯。
- 主要终点完全缓解时间的组间比较:HR 1.35,95%CI 0.68-2.69;P=0.39。
- 泼尼松累积剂量组间差值:-1214,95%CI -2225至-70;P=0.03。
- 基线Pemphigus Disease Area Index ≥15患者事后分析:HR 1.87,P=0.17。
临床怎么用
- 对于天疱疮患者,辅助免疫吸附可作为减少糖皮质激素累积剂量的选择,但需关注严重不良事件风险。
- 广泛病变患者可能从辅助免疫吸附中更早获益,但该结论来自事后分析,需个体化评估。
- 治疗决策应结合患者病变范围、安全性风险与预期获益综合权衡。
局限性
- 研究因安全性问题提前终止,样本量有限(72例),可能影响统计效能。
- 广泛病变患者的缓解时间优势来自事后分析,证据级别有限。
- 严重不良事件在BMT+IA组更频繁,需在临床应用中密切监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are potentially life-threatening autoimmune blistering diseases. Treatment is based on long-term immunosuppression with high doses of glucocorticosteroids in combination with potentially corticosteroid-sparing agents and/or rituximab. Immunoadsorption (IA) has emerged as a fast-acting adjuvant treatment option. OBJECTIVES: To assess the clinical efficacy of IA in addition to best medical treatment (BMT). METHODS: We conducted a multicentre (26 centres from Germany and Austria) randomized controlled trial in 72 patients with newly diagnosed, relapsed or chronic active PV or PF (34 female patients and 38 male patients, aged 42-72 years) comparing BMT (prednisolone 1.0 mg kg-1 per day plus azathioprine or mycophenolate) with adjuvant IA (BMT + IA). Central 1 : 1 randomization was done at the coordinating centre for clinical trials (KKS Marburg). The primary endpoint was analysed using Kaplan-Meier and Cox regression methods. RESULTS: The study was ended prematurely owing to safety concerns after random allocation of 72 patients to BMT + IA (n = 34) or BMT (n = 38). The primary endpoint, time to complete remission on therapy, was not significantly different for the two groups [hazard ratio (HR) 1.35, 95% confidence interval (CI) 0.68-2.69; P = 0.39]. The cumulative dose of prednisolone was significantly lower in the BMT + IA group compared with BMT alone (difference -1214, 95% CI -2225 to -70; P = 0.03). In a post hoc analysis, patients with more extensive PV/PF showed a tendency towards a shorter time to remission in the BMT + IA group compared with the BMT group (HR 1.87, P = 0.17 in patients with baseline Pemphigus Disease Area Index ≥ 15). While more adverse events were observed in patients in the BMT group (29 vs. 25), severe adverse events were more frequent in patients in the BMT + IA group (17 events in 10 patients vs. 11 events in 8 patients). CONCLUSIONS: In this study, adjuvant IA did not demonstrate a shorter time to clinical remission, but a corticosteroid-sparing effect was observed. In patients with extensive PV/PF, post hoc analysis suggests that adjuvant IA may lead to earlier remission, but potential adverse events must be carefully weighed against the expected benefits. Pemphigus vulgaris and pemphigus foliaceus are potentially life-threatening autoantibody-driven blistering diseases, which present with erosions or blisters on skin and/or mucous membranes. Treatment is based on long-term immunosuppressive agents. Immunoadsorption (IA) is a procedure that removes autoantibodies from the blood and has emerged as a fast-acting treatment option for pemphigus.We conducted a trial comparing best medical treatment (BMT) (prednisolone 1.0 mg kg per day plus azathioprine or mycophenolate) with best medical treatment plus IA (BMT + IA). A total of 26 centres from Germany and Austria recruited 72 patients with active pemphigus (34 women and 38 men, aged 42–72 years) who were randomly allocated in a ratio of 1 : 1 to the treatment groups.Following inclusion of 72 patients in the BMT + IA (n = 34) or BMT (n = 38) groups, the study ended prematurely owing to safety concerns. The main outcome, time to complete remission (relief of all symptoms) while still receiving therapy, was not significantly different for the two groups. In contrast, the cumulative dose of prednisolone was significantly lower in the BMT + IA compared with BMT alone. In an additional analysis, patients with more extensive pemphigus showed a tendency towards a shorter time to remission in the BMT + IA group compared with the BMT group. While more adverse events were observed in the BMT group (29 vs. 25), severe adverse events were more frequent in the BMT + IA group (17 vs. 11). In this study, IA did not show a shorter time to clinical remission, but a prednisolone-sparing effect was observed. In patients with extensive pemphigus, adjuvant IA may possibly lead to earlier remission, but potential adverse events must be carefully weighed against the expected benefits.
引用
- van Beek N, Eming R, Reuss A, et al. Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomized controlled trial. Br J Dermatol. 2024. PMID: 38133541. doi:10.1093/bjd/ljad489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。